Publications by authors named "Julia Rotow"

Claim this Profile
P
Presenting Features and Causes of Diagnostic Delays: A Report From the NUT Carcinoma Registry.
Sara A Walton, Justin J Kim, Francesco Paoloni, Jean W Liew, Danielle Haradon, Julia K Rotow

JCO Precis Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular Tumor Boards: A Consensus Statement From the International Association for the Study of Lung Cancer.
Mihaela Aldea, Julia K Rotow, Maria Arcila, Matthew Hatton, Lynette Sholl

J Thorac Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-Line MET Tyrosine Kinase Inhibitors versus Immunotherapy ± Chemotherapy for Patients with MET Exon 14 Skipping Mutant Metastatic NSCLC.
Federica Pecci, Hui Li, Alessandro Di Federico, Jia Wu, Hong Chen, Julia Rotow

Clin Cancer Res· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes with neoadjuvant osimertinib and/or chemotherapy in patients with EGFR-mutant resectable non-small cell lung cancers.
Prashasti Agrawal, Julia Rotow, Gaetano Rocco, William Travis, Eduardo Ortiz

Lung Cancer· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical strategies for lung cancer management: Recommendations from the Bridging the Gaps Lung Cancer Consensus Conference 2024.
Narjust Florez, Sandip Patel, Heather A Wakelee, Julia Rotow, Elaine Shum

Cancer· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Expression of Membrane Targets for Therapeutics in RET-Positive Non-Small Cell Lung Cancer.
Arianna Marinello, Maria Rosa Ghigna, Julia K Rotow, Tolulope Adeyelu, Giulio Metro

JAMA Oncol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mitigation and management of adverse events associated with amivantamab therapy.
Narjust Florez, Nicole R LeBoeuf, Julia Rotow, Jennifer A Marks, Joshua K Sabari

Oncologist· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Plasma epigenomic profiling reveals treatment-emergent squamous transformation in prostate cancer.
Karl Semaan, Rashad Nawfal, John Canniff, Hunter Savignano, Ji-Heui Seo, Julia K Rotow

NPJ Precis Oncol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Navigating First-Line Treatment Options for Patients With Epidermal Growth Factor Receptor-Positive Non-Small Cell Lung Cancer.
Giulia La Cava, Alessio Cortellini, Julia K Rotow, Jessica R Bauman

Am Soc Clin Oncol Educ Book· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors.
Ferdinandos Skoulidis, Haniel A Araujo, Minh Truong Do, Yu Qian, Xin Sun, Julia Rotow

Nature· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors.
Ferdinandos Skoulidis, Haniel A Araujo, Minh Truong Do, Yu Qian, Xin Sun, Julia Rotow

Nature· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BLU-945, a potent and selective next-generation EGFR TKI, has antitumor activity in models of osimertinib-resistant non-small-cell lung cancer.
Sun Min Lim, Stefanie S Schalm, Eun Ji Lee, Sewon Park, Chiara Conti, Julia Rotow

Ther Adv Med Oncol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant Osimertinib for the Treatment of Stage I-IIIA Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: A Phase II Multicenter Study.
Collin M Blakely, Anatoly Urisman, Matthew A Gubens, Claire K Mulvey, Greg M Allen, Julia K Rotow

J Clin Oncol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The ASCENT Trial: a phase 2 study of induction and consolidation afatinib and chemoradiation with or without surgery in stage III EGFR-mutant NSCLC.
Allison E B Chang, Andrew J Piper-Vallillo, Raymond H Mak, Michael Lanuti, Alona Muzikansky, Julia Rotow

Oncologist· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Focal adhesion kinase-YAP signaling axis drives drug-tolerant persister cells and residual disease in lung cancer.
Franziska Haderk, Yu-Ting Chou, Lauren Cech, Celia Fernández-Méndez, Johnny Yu, Julia K Rotow

Nat Commun· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response to Dabrafenib Plus Trametinib in a Patient With an Uncommon Activating BRAF Mutation: A First in Non-Small Cell Lung Cancer.
John A Sharp, Daniel Jones, Julia K Rotow, Panos M Fidias, Erin Bertino

J Natl Compr Canc Netw· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Genomic Profile of EGFR Second-Site Mutations and Other Osimertinib Resistance Mechanisms and Clinical Landscape of NSCLC Post-Osimertinib.
Julia K Rotow, Jessica K Lee, Russell W Madison, Geoffrey R Oxnard, Pasi A Jänne

J Thorac Oncol· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The role of APOBEC3B in lung tumor evolution and targeted cancer therapy resistance.
Deborah R Caswell, Philippe Gui, Manasi K Mayekar, Emily K Law, Oriol Pich, Julia K Rotow

Nat Genet· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment decision for recurrences in non-small cell lung cancer during or after adjuvant osimertinib: an international Delphi consensus report.
Myriam Mirza, Aseem Shrivastava, Cecile Matthews, Natasha Leighl, Calvin S H Ng, Julia Rotow

Front Oncol· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genotype Versus Phenotype: Defining Predictive Biomarkers of Immunotherapy Response.
Maisam Makarem, Julia K Rotow

J Thorac Oncol· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anaphylaxis and systemic mastocytosis controlled with KIT inhibitors in a patient with metastatic lung adenocarcinoma.
Camellia L Hernandez, Donna-Marie Lynch, Abby Jane Golash, Kathleen Marquis, Kylie Marie Besz, Julia Rotow

Ann Allergy Asthma Immunol· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pneumonitis in Patients Receiving Thoracic Radiotherapy and Osimertinib: A Multi-Institutional Study.
Leou Ismael Banla, Alice Tzeng, John P Baillieul, Melin J Kandekhar, Kelly J Fitzgerald, Julia K Rotow

JTO Clin Res Rep· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Amplification of Wild-Type Represents a Novel Molecular Subtype of Several Cancer Types With Clinical Response to Selpercatinib.
Malini M Gandhi, Biagio Ricciuti, Guilherme Harada, Matteo Repetto, Melissa S Gildenberg, Julia Rotow

JCO Precis Oncol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Osimertinib and Selpercatinib Efficacy, Safety, and Resistance in a Multicenter, Prospectively Treated Cohort of EGFR-Mutant and RET Fusion-Positive Lung Cancers.
Julia Rotow, Jyoti D Patel, Matthew P Hanley, Helena Yu, Mark Awad

Clin Cancer Res· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeted Therapy for Non-Small Cell Lung Cancer: First Line and Beyond.
Elliott Brea, Julia Rotow

Hematol Oncol Clin North Am· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis